Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
ALKS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.56 - $36.45
Previous CloseN/A
Volume176.14K
Average Volume (3M)1.67M
Market Cap
$4.77B
Enterprise Value$3.87B
Total Cash (Recent Filing)$399.81M
Total Debt (Recent Filing)$74.10M
Price to Earnings (P/E)13.9
Beta0.83
Next Earnings
Oct 22, 2025EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding165,077,970
10 Day Avg. Volume1,370,059
30 Day Avg. Volume1,665,637
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit2.92
Enterprise Value/Ebitda8.65
Forecast
1Y Price Target
$40.32Price Target Upside39.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAlkermes reported a 14% year-over-year increase in net sales for 2Q, driven by growth demand for all three products and one-time positive gross-to-net adjustments.
Product PotentialAlixorexton demonstrated statistically significant and dose-dependent improvements on MWT compared to placebo, achieving normative wakefulness in NT1 patients.
Sales PerformanceLybalvi sales were about 5% higher than consensus, driven by prescription growth.
Bears Say
Adverse EffectsThere are lingering concerns regarding visual disturbances as a potential adverse effect, which the company did not address in the limited release.
Competitive EnvironmentIt is challenging to understand the value of disclosing a complete dataset vs piecemeal in this competitive environment.
Investor ConcernsSeveral important questions remain unaddressed which has raised investor concerns on the competitiveness of the profile and resulted in ALKS trading net -6% since the NT1 data was toplined.
Alkermes News
ALKS FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was $25.56 and its highest was $36.45 in the past 12 months.
What is Alkermes’s market cap?
Alkermes’s market cap is $4.77B.
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Oct 22, 2025 which is in 46 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Jul 29, 2025. The company reported $0.668 earnings per share for the quarter, beating the consensus estimate of $0.356 by $0.312.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes does not currently pay dividends.
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is 0.4.
How many shares outstanding does Alkermes have?
Alkermes has 165,077,970 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of $0.668 in its last earnings report, beating expectations of $0.356. Following the earnings report the stock price went up 3.25%.
Which hedge fund is a major shareholder of Alkermes?
Currently, no hedge funds are holding shares in ALKS
Alkermes Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.32 (39.42% Upside)
$40.32 (39.42% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.33%
12-Months-Change
Fundamentals
Return on Equity
23.94%
Trailing 12-Months
Asset Growth
2.08%
Trailing 12-Months
Company Description
Alkermes
Alkermes (ALKS) is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, including addiction and mental health conditions. The company operates primarily in the biopharmaceutical sector and specializes in the commercialization of products designed to treat diseases such as schizophrenia, depression, and opioid dependence. Alkermes' core products include Vivitrol, an injectable medication used to treat opioid and alcohol dependence, and Aristada, an injectable formulation for the treatment of schizophrenia.
ALKS Company Deck
ALKS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Alkermes, with strong financial results, successful clinical trial outcomes, and a robust cash position. However, increased R&D expenses and variability in cataplexy endpoint results present challenges.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$40.32
▲(39.42% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Blueprint Medicines
―
Axsome Therapeutics
―
Krystal Biotech
―
Ownership Overview
1.41% Insiders
31.50% Mutual Funds
25.07% Other Institutional Investors
11.40% Public Companies and
Individual Investors